Chirayu Govind Patel, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma | 4 | 2023 | 1877 | 1.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2023 | 1378 | 1.340 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2023 | 1270 | 0.860 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 233 | 0.760 |
Why?
|
| Hodgkin Disease | 2 | 2020 | 1415 | 0.760 |
Why?
|
| Titanium | 1 | 2023 | 494 | 0.720 |
Why?
|
| Multiple Myeloma | 4 | 2023 | 5181 | 0.710 |
Why?
|
| Mycosis Fungoides | 2 | 2020 | 163 | 0.690 |
Why?
|
| Mediastinal Neoplasms | 1 | 2022 | 423 | 0.690 |
Why?
|
| Electrons | 1 | 2017 | 268 | 0.540 |
Why?
|
| Scalp | 1 | 2017 | 380 | 0.480 |
Why?
|
| Education | 1 | 2017 | 543 | 0.480 |
Why?
|
| Treatment Refusal | 1 | 2017 | 421 | 0.470 |
Why?
|
| Central Nervous System Diseases | 1 | 2017 | 518 | 0.440 |
Why?
|
| Osteonecrosis | 1 | 2014 | 227 | 0.420 |
Why?
|
| Antigens, CD19 | 2 | 2023 | 380 | 0.380 |
Why?
|
| Bone Remodeling | 1 | 2014 | 575 | 0.370 |
Why?
|
| Diphosphonates | 1 | 2014 | 623 | 0.340 |
Why?
|
| Imidazoles | 1 | 2014 | 1206 | 0.310 |
Why?
|
| Protons | 2 | 2023 | 1127 | 0.300 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 773 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5442 | 0.240 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2023 | 1624 | 0.240 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2023 | 140 | 0.210 |
Why?
|
| Fractures, Compression | 1 | 2023 | 133 | 0.200 |
Why?
|
| Organs at Risk | 1 | 2022 | 346 | 0.180 |
Why?
|
| Radiation Pneumonitis | 1 | 2020 | 104 | 0.180 |
Why?
|
| Mediastinum | 1 | 2020 | 267 | 0.170 |
Why?
|
| Radiotherapy Dosage | 2 | 2022 | 2879 | 0.160 |
Why?
|
| Radiometry | 1 | 2023 | 800 | 0.150 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 2124 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 1770 | 0.140 |
Why?
|
| Spinal Fractures | 1 | 2023 | 696 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2023 | 1357 | 0.140 |
Why?
|
| Humans | 20 | 2023 | 744343 | 0.140 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 2016 | 0.120 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 2480 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2540 | 0.120 |
Why?
|
| Radiotherapy | 2 | 2020 | 1533 | 0.120 |
Why?
|
| Artifacts | 1 | 2023 | 1904 | 0.120 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 2645 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2023 | 10252 | 0.110 |
Why?
|
| Neoplasms | 2 | 2019 | 21683 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 11031 | 0.100 |
Why?
|
| Collagen Type I | 1 | 2014 | 592 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2023 | 77449 | 0.100 |
Why?
|
| Bone Resorption | 1 | 2014 | 723 | 0.090 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 5686 | 0.090 |
Why?
|
| Heart | 1 | 2022 | 4467 | 0.080 |
Why?
|
| Prognosis | 2 | 2023 | 29063 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2019 | 7729 | 0.070 |
Why?
|
| Cause of Death | 1 | 2017 | 3584 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3870 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 808 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3479 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 9239 | 0.060 |
Why?
|
| Quality of Life | 2 | 2023 | 12804 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2017 | 3481 | 0.050 |
Why?
|
| Middle Aged | 6 | 2020 | 213383 | 0.050 |
Why?
|
| Peptides | 1 | 2014 | 4409 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 53288 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 2245 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 20129 | 0.040 |
Why?
|
| Male | 7 | 2023 | 350118 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2020 | 63114 | 0.040 |
Why?
|
| Cytokines | 1 | 2014 | 7322 | 0.040 |
Why?
|
| Aged | 5 | 2020 | 163280 | 0.040 |
Why?
|
| Adult | 3 | 2023 | 214055 | 0.040 |
Why?
|
| Journal Impact Factor | 1 | 2019 | 156 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 8863 | 0.030 |
Why?
|
| Spine | 1 | 2023 | 1144 | 0.030 |
Why?
|
| Infant | 1 | 2017 | 35136 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2019 | 492 | 0.030 |
Why?
|
| Female | 6 | 2023 | 380194 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 56430 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 57776 | 0.030 |
Why?
|
| Child | 2 | 2020 | 77709 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 85781 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2019 | 1486 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 11524 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 39050 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 8340 | 0.020 |
Why?
|
| Cystectomy | 1 | 2013 | 686 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 1662 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 2924 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 3616 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12354 | 0.020 |
Why?
|
| Logistic Models | 1 | 2019 | 13408 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15540 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6895 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2023 | 40561 | 0.010 |
Why?
|
| Time Factors | 1 | 2019 | 40075 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 9959 | 0.010 |
Why?
|
| Risk Factors | 1 | 2020 | 72290 | 0.010 |
Why?
|